相关临床试验
7
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
3
42.9%
招募中
4
57.1%
暂无批准数据
- The European Union has committed €225 million to advance next-generation flu vaccines through clinical trials, representing the largest EU investment ever dedicated to accelerating innovative medical countermeasures. - This marks the first use of pre-commercial procurement by the European Commission to support vaccine candidates through clinical development, with contracts awarded to 10 organizations for 98-month development programs. - The initiative aims to develop vaccines that protect against broader influenza variants, can be rapidly adapted for pandemic strains, and offer alternative administration methods including nasal sprays, oral doses, and skin patches. - The funding addresses persistent scientific challenges in influenza vaccine development, where a 2025 review found that most critical milestones remain unresolved due to scientific complexity and resource constraints.
- Ethris GmbH and the German Center for Infection Research (DZIF) announced a strategic collaboration to develop mRNA-based vaccines for prevention and treatment of infectious diseases. - The partnership combines Ethris' proprietary SNIM®RNA and SNaP LNP® technology platforms with DZIF's translational vaccine research expertise across viruses, bacteria, and parasites. - The collaboration aims to create next-generation mRNA vaccines with enhanced stability, targeted delivery, and variant-ready protection beyond individual respiratory viruses. - Manufacturing support will be provided by Ethris' partners Patheon and Evonik to enable both preclinical and clinical development of advanced vaccine candidates.
